1417 related articles for article (PubMed ID: 24267198)
1. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.
Walker S; Burch J; McKenna C; Wright K; Griffin S; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():13-21. PubMed ID: 21609649
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab for asthma in adults and children.
Normansell R; Walker S; Milan SJ; Walters EH; Nair P
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.
Faria R; McKenna C; Palmer S
Value Health; 2014 Dec; 17(8):772-82. PubMed ID: 25498772
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
Chipps BE; Figliomeni M; Spector S
Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands.
van Nooten F; Stern S; Braunstahl GJ; Thompson C; Groot M; Brown RE
J Med Econ; 2013; 16(3):342-8. PubMed ID: 23216016
[TBL] [Abstract][Full Text] [Related]
9. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
Dewilde S; Turk F; Tambour M; Sandström T
Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab for the treatment of severe persistent allergic asthma.
Jones J; Shepherd J; Hartwell D; Harris P; Cooper K; Takeda A; Davidson P
Health Technol Assess; 2009 Sep; 13 Suppl 2():31-9. PubMed ID: 19804687
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective.
Levy AN; García A Ruiz AJ; García-Agua Soler N; Sanjuan MV
J Asthma; 2015 Mar; 52(2):205-10. PubMed ID: 24995661
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
Zafari Z; Sadatsafavi M; Marra CA; Chen W; FitzGerald JM
PLoS One; 2016; 11(1):e0146003. PubMed ID: 26751790
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
Hanania NA; Alpan O; Hamilos DL; Condemi JJ; Reyes-Rivera I; Zhu J; Rosen KE; Eisner MD; Wong DA; Busse W
Ann Intern Med; 2011 May; 154(9):573-82. PubMed ID: 21536936
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
15. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
Dal Negro RW; Tognella S; Pradelli L
J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
[TBL] [Abstract][Full Text] [Related]
16. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective.
Campbell JD; Spackman DE; Sullivan SD
Allergy; 2010 Sep; 65(9):1141-8. PubMed ID: 20148804
[TBL] [Abstract][Full Text] [Related]
17. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath.
Harnan SE; Tappenden P; Essat M; Gomersall T; Minton J; Wong R; Pavord I; Everard M; Lawson R
Health Technol Assess; 2015 Oct; 19(82):1-330. PubMed ID: 26484874
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab: a review of its use in patients with severe persistent allergic asthma.
McKeage K
Drugs; 2013 Jul; 73(11):1197-212. PubMed ID: 23812924
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
Sullivan PW; Li Q; Bilir SP; Dang J; Kavati A; Yang M; Rajput Y
Curr Med Res Opin; 2020 Jan; 36(1):23-32. PubMed ID: 31491337
[No Abstract] [Full Text] [Related]
20. Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden.
Andersson M; Janson C; Kristensen T; Szende A; Golam S
J Med Econ; 2020 Aug; 23(8):877-884. PubMed ID: 32324093
[No Abstract] [Full Text] [Related]
[Next] [New Search]